ABSTRACT
AIM: Omega-3 fatty acids have emerged as a new option for controlling the residual risk for coronary artery disease (CAD) in the statin era. Eicosapentaenoic acid (EPA) is associated with reduced CAD risk in the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention trial, whereas the Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia trial that used the combination EPA/docosahexaenoic acid (DHA) has failed to derive any clinical benefit. These contradictory results raise important questions about whether investigating the antiatherosclerotic effect of omega-3 fatty acids could help to understand their significance for CAD-risk reduction. METHODS: The Attempts at Plaque Vulnerability Quantification with Magnetic Resonance Imaging Using Noncontrast T1-weighted Technic EPA/DHA study is a single-center, triple-arm, randomized, controlled, open-label trial used to investigate the effect of EPA/DHA on high-risk coronary plaques after 12 months of treatment, detected using cardiac magnetic resonance (CMR) in patients with CAD receiving statin therapy. Eligible patients were randomly assigned to no-treatment, 2-g/day, and 4-g/day EPA/DHA groups. The primary endpoint was the change in the plaque-to-myocardium signal intensity ratio (PMR) of coronary high-intensity plaques detected by CMR. Coronary plaque assessment using computed tomography angiography (CTA) was also investigated. RESULTS: Overall, 84 patients (mean age: 68.2 years, male: 85%) who achieved low-density lipoprotein cholesterol levels of ï¼100 mg/dL were enrolled. The PMR was reduced in each group over 12 months. There were no significant differences in PMR changes among the three groups in the primary analysis or analysis including total lesions. The changes in CTA parameters, including indexes for detecting high-risk features, also did not differ. CONCLUSION: The EPA/DHA therapy of 2 or 4 g/day did not significantly improve the high-risk features of coronary atherosclerotic plaques evaluated using CMR under statin therapy.
Subject(s)
Coronary Artery Disease , Fatty Acids, Omega-3 , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Plaque, Atherosclerotic , Humans , Male , Aged , Plaque, Atherosclerotic/diagnostic imaging , Plaque, Atherosclerotic/drug therapy , Docosahexaenoic Acids , Eicosapentaenoic Acid , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/drug therapy , Fatty Acids, Omega-3/therapeutic useABSTRACT
Maintenance of denitrifying granular sludge for treating soft groundwater (total hardness = 75 mg calcium carbonate/L) in an upflow sludge-blanket reactor was demonstrated with complete removal of applied nitrate (20 mg N/L) over extended operation and a hydraulic residence time of 34 minutes. A high pH of approximately 9.0 was shown to be important for generation of mineral precipitation needed for production of heavy granular sludge with good retention characteristics. As a method of increasing precipitation potential, pH adjustment was determined to be more economically favorable than calcium or alkalinity supplementation. In addition, temporary increases in substrate loading were shown to be effective for enhancing biomass levels in a manageable granular sludge. The significance of biomass in promoting mineral precipitation was discussed.